This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hong, M. K. Articles by Kent, K. M. Search for Related Content PubMed PubMed Citation Articles by Hong, M. K. Articles by Kent, K. M.

Circulation, Vol 88, 638-648, Copyright © 1993 by American Heart Association

ARTICLES

The effect of porous infusion balloon-delivered angiopeptin on myointimal hyperplasia after balloon injury in the rabbit

MK Hong, T Bhatti, BJ Matthews, KS Stark, SS Cathapermal, ML Foegh, PW Ramwell and KM Kent
Department of Cardiology, Washington Hospital Center, Washington, DC 20010-2975.

BACKGROUND. Angiopeptin, a synthetic somatostatin analogue, reduces myointimal hyperplasia after experimental balloon angioplasty when given subcutaneously. The feasibility and efficacy of a single dose of angiopeptin delivered locally via the Wolinsky porous balloon on myointimal hyperplasia were studied. METHODS AND RESULTS. Three rabbits received 125I-angiopeptin in the mid abdominal aorta via the Wolinsky balloon at 5 atm for 1 minute after balloon injury. Thirty minutes later, autoradiography demonstrated radioactivity in the media and the adventitia. Forty rabbits were divided equally into one control group receiving saline and three angiopeptin groups receiving 1, 10, or 100 micrograms/mL of angiopeptin delivered locally at 5 atm for 1 minute via the Wolinsky balloon into the mid abdominal aorta after balloon injury of the entire abdominal aorta. On day 21, the abdominal aortas were fixed in situ and harvested. There was no statistical difference in the amount of myointimal hyperplasia in the locally treated aorta in the angiopeptin groups compared with the control group. However, in the lower abdominal aorta, where balloon injury without local delivery was performed, there was a significant reduction of myointimal hyperplasia in the highest-concentration angiopeptin group (P < .001 versus the control group). Electron microscopy showed that the control animals had a pseudointima of smooth muscle cells throughout the aorta, whereas in all the angiopeptin-treated animals, endothelial cells were present at both locations. CONCLUSIONS. Angiopeptin can be delivered intramurally via the Wolinsky porous balloon and reduces myointimal hyperplasia only in the area distal to the local drug delivery site (downstream effect), possibly by healing the injured endothelium, by transport via the vasa vasora, and/or by systemic effect.

This article has been cited by other articles:

				N. F. Meneveau, B. D. Klugherz, B. Chaquor, M. A. Golden, M. M. Jouille, E. Macarek, P. B. Weisz, and R. L. Wilensky Separate and Combined Effects of Local and Continuous Intravenous Administration of {beta}-Cyclodextrin Tetradecasulfate on Intimal Hyperplasia after Angioplasty in Porcine Coronary Arteries Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 53 - 60. [Abstract] [PDF]

				N Meneveau, F Schiele, G Grollier, B Farah, J.M Lablanche, K Khalife, J Machecourt, N Danchin, J.E Wolf, M Simpson, et al. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS Trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study Eur. Heart J., November 1, 2000; 21(21): 1767 - 1775. [Abstract] [PDF]

				S. B. Curtis, J. Hewitt, S. Yakubovitz, A. Anzarut, Y. N. Hsiang, and A. M. J. Buchan Somatostatin receptor subtype expression and function in human vascular tissue Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H1815 - H1822. [Abstract] [Full Text] [PDF]

				S. KHARE, U. KUMAR, R. SASI, L. PUEBLA, L. CALDERON, K. LEMSTROM, P. HAYRY, and A. Y. C. PATEL Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty FASEB J, February 1, 1999; 13(2): 387 - 394. [Abstract] [Full Text]

				B. D. Klugherz, N. Meneveau, W. Chen, F. Wade-Whittaker, G. Papandreou, R. Levy, and R. L. Wilensky Sustained Intramural Retention and Regional Redistribution Following Local Vascular Delivery of Polylactic-Coglycolic Acid and Liposomal Nanoparticulate Formulations Containing Probucol Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(3): 167 - 174. [Abstract] [PDF]

				A. Lafont and D. Faxon Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, July 1, 1998; 39(1): 50 - 59. [Full Text] [PDF]

				C. R. White, J. Shelton, S.-J. Chen, V. Darley-Usmar, L. Allen, C. Nabors, P. W. Sanders, Y.-F. Chen, and S. Oparil Estrogen Restores Endothelial Cell Function in an Experimental Model of Vascular Injury Circulation, September 2, 1997; 96(5): 1624 - 1630. [Abstract] [Full Text]

				M. K. Hong, K. M. Kent, R. Mehran, G. S. Mintz, F. O. Tio, M. Foegh, S. C. Wong, S. S. Cathapermal, and M. B. Leon Continuous Subcutaneous Angiopeptin Treatment Significantly Reduces Neointimal Hyperplasia in a Porcine Coronary In-Stent Restenosis Model Circulation, January 21, 1997; 95(2): 449 - 454. [Abstract] [Full Text]

				A. Lucas, L.-y. Liu, J. Macen, P. Nash, E. Dai, M. Stewart, K. Graham, W. Etches, L. Boshkov, P. N. Nation, et al. Virus-Encoded Serine Proteinase Inhibitor SERP-1 Inhibits Atherosclerotic Plaque Development After Balloon Angioplasty Circulation, December 1, 1996; 94(11): 2890 - 2900. [Abstract] [Full Text]

				S. M. Schwartz, D. deBlois, and E. R. M. O'Brien The Intima : Soil for Atherosclerosis and Restenosis Circ. Res., September 1, 1995; 77(3): 445 - 465. [Full Text]